Observational studyAlzheimer's & dementia : the journal of the Alzheimer's Association2026
APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD study.
Observational study in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of plasma p-tau217 against amyloid PET: A meta-analysis of technical platform variability and ratio versus single marker comparisons.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
introductionWe evaluated whether apolipoprotein E (APOE εε4) genotype-guided lecanemab escalation mitigates the APOE εε4-driven amyloid-related imaging abnormalities (ARIA) with edema (ARIA-E) gradient and whether ARIA-E and ARIA with hemosiderin deposition (ARIA-H) are mechanistically distinct.
methodsFive hundred eight patients with early Alzheimer's disease received APOE genotype-guided lecanemab escalation (target maximum plasma concentration [Cmax] thresholds: 118, 308, and 404 µg/mL for εε4/εε4, heterozygote, and non-carrier) across eight Korean centers, with magnetic resonance imaging-based ARIA surveillance.
resultsARIA-E incidence was 2.0% in non-carriers and 6.2% in εε4/εε4 homozygotes (εε4/εε4-versus-non-carrier OR 3.25, versus 8.49 in Clarity AD and 8.32 in Japan post-marketing surveillance). Any ARIA-H was independently predicted by baseline cerebral microbleeds, white matter hyperintensity (WMH), age, and APOE εε4 allele dose (aORs 1.23, 1.50, 1.04, 1.75). DISCUSSION: Under genotype-guided escalation, observations are compatible with - but do not establish - attenuation of the APOE εε4-driven ARIA-E gradient, whereas ARIA-H risk reflected baseline cerebrovascular burden. These findings raise the hypothesis of a dual-axis safety framework requiring randomized confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.